Ping Zhang
CIK 2050176 · View on SEC EDGAR ↗
First SEC filing: June 30, 2026 · Latest: June 30, 2026
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 10, 2026 | GYRE | A | 40,000 | — | — | 40,000 Direct | — | Acquired | (price as of 2026-08-21) |
| May 14, 2026 | GYRE | D | 250,000 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-21) |
| Jan. 7, 2026 | GYRE | A | 100,000 | — | — | 100,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Aug. 5, 2025 | GYRE | A | 250,000 | — | — | 250,000 Direct | — | Acquired | (price as of 2026-08-21) |
| May 27, 2025 | GYRE | A | 250,000 | — | — | 250,000 Direct | — | Acquired | (price as of 2026-08-21) |
| Jan. 5, 2025 | GYRE | A | 52,000 | — | — | 52,000 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 10, 2026 | GYRE | Stock Option (Right to Buy) | Common Stock (40,000) | $5.95 | June 10, 2036 | 40,000 | Acquired |
| May 14, 2026 | GYRE | Stock Option (Right to Buy) | Common Stock (250,000) | $10.18 | May 27, 2035 | 250,000 | Disposed |
| Jan. 7, 2026 | GYRE | Stock Option (Right to Buy) | Common Stock (100,000) | $7.31 | Jan. 7, 2036 | 100,000 | Acquired |
| Aug. 5, 2025 | GYRE | Stock Option (Right to Buy) | Common Stock (250,000) | $6.92 | Aug. 5, 2035 | 250,000 | Acquired |
| May 27, 2025 | GYRE | Stock Option (Right to Buy) | Common Stock (250,000) | $10.18 | May 27, 2035 | 250,000 | Acquired |
| Jan. 5, 2025 | GYRE | Stock Option (Right to Buy) | Common Stock (52,000) | $10.79 | Jan. 5, 2035 | 52,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
GYRE
CEO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $189,777 | — | — | $3,795,596 | $100,000 | — | $11,250 | $4,096,623 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.